These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8609902)

  • 1. Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells.
    Anyanwutaku IO; Guo X; Chen HX; Ji Z; Lee KH; Cheng YC
    Mol Pharmacol; 1996 Apr; 49(4):721-6. PubMed ID: 8609902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants.
    Liu SY; Hwang BD; Haruna M; Imakura Y; Lee KH; Cheng YC
    Mol Pharmacol; 1989 Jul; 36(1):78-82. PubMed ID: 2546053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
    Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
    Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
    J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
    Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC
    Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
    Ganapathi R; Constantinou A; Kamath N; Dubyak G; Grabowski D; Krivacic K
    Mol Pharmacol; 1996 Aug; 50(2):243-8. PubMed ID: 8700130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
    Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
    J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 4 beta-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents.
    Hu C; Xu D; Du W; Qian S; Wang L; Lou J; He Q; Yang B; Hu Y
    Mol Biosyst; 2010 Feb; 6(2):410-20. PubMed ID: 20094661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipyridamole reverses the resistance to topoisomerase II inhibitors but not to antimicrotubule agents in multidrug-resistant melanoma cells.
    Damle B; Desai P
    Oncol Res; 1994; 6(2):49-57. PubMed ID: 7949465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
    Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
    Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants.
    Chang JY; Han FS; Liu SY; Wang ZQ; Lee KH; Cheng YC
    Cancer Res; 1991 Apr; 51(7):1755-9. PubMed ID: 1848478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
    Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
    Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
    Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of P-glycoprotein associated multidrug resistance by new isoprenoid derivatives.
    Hayashi M; Koike K; Rho MC; Kuwano M; Kishiye T; Komiyama K
    Anticancer Drug Des; 2001; 16(4-5):255-60. PubMed ID: 12049484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.